Clinical Trial Update: Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer [Phase 2]

View source ↗

Summary

Open-label Phase 2 study evaluating the combination of Avutometinib, Defactinib, and Cetuximab in unresectable, anti-EGFR-refractory advanced colorectal cancer …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Avutometinib (avutometinib)
• Cetuximab (cetuximab)
• Defactinib (defactinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Advanced Colorectal Cancer | Phase 2 | Status: RECRUITING